早期复评可识别门诊晚期心衰高危轨迹
REVIVAL前瞻性观察研究纳入400例门诊晚期心衰患者,在入组120天内进行INTERMACS分级的早期复评。325例完成复评者中24%出现INTERMACS分级恶化,其1年内死亡、紧急MCS或紧急移植的复合终点发生率显著升高(28% vs 15%),校正基线后风险比2.2。早期复评有助于识别高危患者并指导晚期治疗分流。
要点
- 门诊晚期心衰患者早期复评中约24%出现INTERMACS分级恶化
- 分级恶化者1年内死亡、紧急MCS或紧急移植风险显著升高(HR 2.2)
- 建议对门诊晚期心衰患者进行早期复评以指导治疗分流
核心结论
- 早期复评可识别门诊晚期心衰中INTERMACS分级恶化的患者,其后1年结局更差。
- 建议对门诊晚期心衰患者进行早期复评,以更好定义疾病轨迹并指导晚期治疗分流。
研究设计与样本
- REVIVAL为前瞻性观察研究,2015-2016年从21个MCS/移植中心纳入400例门诊晚期心衰患者。
- 研究设计包括入组后120天内对INTERMACS分级进行临床复评。
主要发现
- 400例中325例(81%)完成早期复评,其中24%出现INTERMACS分级恶化。
- 分级恶化与更长心衰病史和更差基线INTERMACS分级相关,但基线LVEF(中位数0.20)、6分钟步行、生活质量等无差异。
临床怎么用
- 对门诊晚期心衰患者在入组后120天内进行INTERMACS分级早期复评,以识别分级恶化者。
- 对早期复评显示INTERMACS分级恶化的患者,应加强监测并考虑 advanced therapies 的分流评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with ambulatory advanced heart failure (HF) are increasingly considered for durable mechanical circulatory support (MCS) and heart transplantation and their effective triage requires careful assessment of the clinical trajectory. METHODS: REVIVAL, a prospective, observational study, enrolled 400 ambulatory advanced HF patients from 21 MCS/transplant centers in 2015-2016. Study design included a clinical re-assessment of Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile within 120 days after enrollment. The prognostic impact of a worsening INTERMACS Profile assigned by the treating physician was assessed at 1 year after the Early Relook. RESULTS: Early Relook was done in 325 of 400 patients (81%), of whom 24% had a worsened INTERMACS Profile, associated with longer HF history and worse baseline INTERMACS profile, but no difference in baseline LVEF (median 0.20), 6-minute walk, quality of life, or other baseline parameters. Early worsening predicted higher rate of the combined primary endpoint of death, urgent MCS, or urgent transplant by 1 year after Early Relook, (28% vs 15%), with hazard ratio 2.2 (95% CI 1.2- 3.8; p = .006) even after adjusting for baseline INTERMACS Profile and Seattle HF Model score. Deterioration to urgent MCS occurred in 14% vs 5% (p = .006) during the year after Early Relook. CONCLUSIONS: Early Relook identifies worsening of INTERMACS Profile in a significant population of ambulatory advanced HF, who had worse outcomes over the subsequent year. Early reassessment of ambulatory advanced HF patients should be performed to better define the trajectory of illness and inform triage to advanced therapies.
引用
- Kittleson MM, Ambardekar AV, Stevenson LW, et al. An early relook identifies high-risk trajectories in ambulatory advanced heart failure. J Heart Lung Transplant. 2021. PMID: 34629234. doi:10.1016/j.healun.2021.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。